en · de · es · fr · pt
sr9009-notes.peptides9000.com › Wiki › Analytical Detection And Regulatory Status — Research Overview

Analytical Detection And Regulatory Status — Research Overview

By Editorial Desk · published 2026-06-30 · last reviewed 2026-08-01 · Wiki

If you have been reading about freeze-thaw and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Sr9009 at a glance

PropertyValueNotes
Regulatory statusNot approved for human useInvestigational status in most countries
Sports statusProhibited by WADAClassified as non-approved or metabolic modulator
Common analytical methodLC-MS/MSUsed for trace detection in biological samples
Typical test matricesUrine and bloodSample choice depends on testing program
Human trial dataNone publishedEffects and safety are not established

Analytical and Handling Considerations

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Related pages on this site

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

Background and Mechanism

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Notes from published material

=== Stone India === Jupiter Wagons Ltd was selected as the successful resolution applicant by the Committee of Creditors of Stone India Ltd, which used to supply electrical engineering products to Indian Railways such as Pantograph. Both JWL and Stone India being engaged in the same line of activity, the acquisition of Stone India by JWL was thereby slated to provide natural synergy to the company.

Helena was an art installation by Marco Evaristti originally at the Trapholt museum in 2000. The art consisted of a room with 10 blenders, each of which contained a green swordtail (often misreported as goldfish). The fish were vulnerable to any visitor to the exhibit who chose to turn on a blender and kill them. During the exhibition two fish were killed in this way. Persons present at the initial exhibition of the installation noted that "numerous media representatives who were present... virtually encouraged the visitors to press the button in order to initiate a scandal". Legal complaints resulted in the blenders being unplugged, though the installation remained on display.

Australia: Offshore detention centres: Beginning in 2001, Australia implemented border control policies featuring the detention of asylum seekers and economic migrants who arrived unlawfully by boat in nearby islands in the Pacific. These policies are controversial, and in 2017, the Supreme Court of Papua New Guinea declared the detention centre at the Manus Island unconstitutional. The adherence of these policies to international human rights law is a matter of controversy. Travel restrictions on Australian citizens during the COVID-19 pandemic: During the COVID-19 pandemic, Australia adopted a policy of denying entry to its own citizens arriving from jurisdictions perceived to pose a high risk of COVID-19 transmission. Additionally, Australia adopted a broad policy of restricting entry to the country for all individuals located overseas, including Australian citizens, resulting in a large number of Australian citizens stranded abroad. Australia's policies concerning its own citizens undermined the principle in international law that a state must permit entry to its own citizens, as enshrined in the International Covenant on Civil and Political Rights. At the same time, the Australian government prohibited most Australian citizens from leaving the country, even if they ordinarily reside overseas.

Sources: en.wikipedia.org

Background from the literature

== Enzyme mechanism == The main reaction is an SN2 displacement of the halogen for a hydroxyl group derived from water. To begin, aspartate 124 is perfectly aligned with the substrate. It will drive off the halogen and form an ester functionality carbon-oxygen bond. Following this displacement is a hydrolysis reaction by utilizing the imidazole ring of histidine 289 as the general base. This will deprotonate water, form a tetrahedral intermediate at the original ester, and create an imidazolium cation at histidine. The final step is beta-elimination. With a newly formed imidazolium cation ready to be an acid, aspartate 124 reverts to its original acidic state and breaks the ester linkage, as well as deprotonating histidine 289. The alcohol is eliminated and the halogen is now a free anion. Also taking place in a facilitating role are tryptophan groups in the periphery of the active site. These residues provide hydrogen bond donor groups to the chloride as it begins to undergo the SN2 reaction and become an anion. A second tryptophan also provides rigidity through a stable peptide bond to aspartate 124. It holds the beta-carbon oxygen in place so that it’s in prime position to make the ester linkage.

Periodic counter-current chromatography puts this problem aside by utilizing more than one column. PCC processes can be run with any number of columns, starting from two. The following paragraph will explain a two-column version of PCC, but other protocols with more columns rely on the same principles (see below). A diagram depicting the individual process steps is shown on the right. In Step 1, the so-called sequential loading phase, columns 1 and 2 are interconnected. Column 1 is fully loaded with sample (red) while its breakthrough is captured on column 2. In Step 2, column 1 is washed, eluted, cleaned and re-equilibrated while loading separately continues on column 2. In Step 3, after regeneration of column 1, the columns are again inter-connected and column 2 is fully loaded while its breakthrough is captured on column 1. Finally, in Step 4 column 2 is washed, eluted, cleaned and re-equilibrated while loading continues independently on column 1. This cyclic process is repeated in a continuous way. Several variations of periodic counter-current chromatography with more than two columns exist. In these cases, additional columns are either placed within the feed stream during loading, having the same effect as using longer columns. Alternatively, additional columns can be kept in an unoccupied stand-by mode during loading. This mode offers additional assurance that the main process is not influenced by washing and cleaning protocols, albeit in practice this is rarely required.

==== In cattle ==== Canadian researchers used yearling heifers to determine the relative pain of the two branding methods. Thirty animals were randomly assigned either a hot, freeze or sham branding. Blood samples were drawn every 20 minutes, beginning 20 minutes before branding and for 3 hours after. Each heifer in the hot group was branded with three separate steel irons for a total of 9–15 seconds (3–5 seconds per iron), while heifers in the freeze group were branded with three separate copper irons (of the same design as the hot group) for a total of 60 seconds (20 seconds per iron). Cattle in the sham group were placed in the same squeeze chute used for the real brandings. The animals were shaved in this restraint and then held there for 3 minutes, the mean duration of the actual brandings. The results showed that both hot and freeze-branded cattle had elevated cortisol levels compared with the sham-branded group. Hot and freeze-branded animals had similar maximum elevations, which occurred 20 minutes after branding. Cortisol levels in the hot-branded group took longer to return to baseline than either the freeze or sham-branded heifers. No significant difference in cortisol concentration was noted between the two branded groups after 40 minutes post-branding. No significant differences between the three groups were detected with the other proxies the experimenters selected for pain (touch sensitivity and stress-induced analgesia). The authors concluded that,

== Publications == Active Biological Evolution: Feedback-Driven, Actively Accelerated Organismal and Cancer Evolution , Frank H. Laukien, 2022 ISBN 979-8-9854147-0-7 Origins & Evolution: Evolution of Our Universe and Planet, and the Origins of Life and Meaning Frank H. Laukien, ISBN 979-8985414721

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Why is SR9009 prohibited in sport?

Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.

How is SR9009 detected in samples?

Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.

Is SR9009 legal?

Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.

Network